Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015;11(4):901-7.
doi: 10.1080/21645515.2015.1010953.

A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine

Shashank Dalvi  1 , Prasad S Kulkarni, M A Phadke, S S More, Sanjay K Lalwani, Dipty Jain, Mamta Manglani, B S Garg, Mohan K Doibale, C T Deshmukh; SIIL DTwP + HepB Hib Author Group
Collaborators, Affiliations
Clinical Trial

A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine

Shashank Dalvi et al. Hum Vaccin Immunother. 2015.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Hum Vaccin Immunother. 2015;11(7):1879. doi: 10.1080/21645515.2015.1057041. Hum Vaccin Immunother. 2015. PMID: 26148332 Free PMC article. No abstract available.

Abstract

Hepatitis B and Haemophilus influenzae type b (Hib) infections are major public health problems in developing countries, including India. Hence, combination vaccines containing DTwP, recombinant hepatitis B and Hib conjugate vaccines have been developed. Here, we report a Phase IV study which assessed safety and reactogenicity of a new DTwP-HepB+Hib vaccine. Three doses of DTwP-HepB+Hib vaccine (Pentavac, Serum Institute of India Ltd) or Tritanrix-HB+Hib (GlaxoSmithKline Beecham) were administered to infants at 6, 10 and 14 weeks of age in 2:1 ratio. The subjects were followed till one month after the third dose for safety assessment. Adverse events were captured in structured diaries and physical examinations were performed on each visit. The study was conducted in 1510 infants. Both vaccines caused injection site local and systemic reactions and the incidence was similar in both the groups. The incidence of local solicited reactions was: tenderness 35.9 %-33.6 %; redness 18.1 %-17.2 %; swelling 23.7 %-22.4 %; induration 12.8 % -13.7 %. The percentage of systemic solicited reactions were: diarrhea 2.2 %-2.2 %; drowsiness 3.3 %-3.4 %; fever 14.0 %-11.2 %; irritability 28.1 %-25.4 %; loss of appetite 6.6 %-5.6 %; persistent crying 17.7 %-15.7 %; vomiting 3.5 %-3.0 %. No serious adverse event was caused by the vaccines. The new DTwP-HepB+Hib combination vaccine showed similar safety profile to that of an imported vaccine in Indian infants.

Keywords: DTwP-HepB+Hib vaccine; infants; reactogenicity; safety.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Flowchart for study subject disposition.
See this image and copyright information in PMC

References

    1. Sokhey J, Kim-Farley RJ, Bhargava I. The expanded programme on immunization: A decade of progress in India. Ann Trop Paediatr 1989 Mar; 9(1):24-9 - PubMed
    1. Dutta S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol J 2008; 5:156; PMID:19099581; http://dx.doi.org/10.1186/1743-422X-5-156. - DOI - PMC - PubMed
    1. Watt JP, Wolfson LJ, O'Brien KL, Henkel E, Deloria-knol M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, et al. . Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: Global estimates. Lancet 2009; 374: 903-11; PMID:19748399; http://dx.doi.org/10.1016/S0140-6736(09)61203-4. - DOI - PubMed
    1. Subcommittee of NTAGI . NTAGI subcommittee recommendations on Haemophilus influenzae type b (Hib) vaccine introduction in India. Indian Pediatr 2009;46:945-54; PMID:19955578. - PubMed
    1. Combination Vaccines for Childhood Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics 1999; 103:1064-1077; PMID:10224194; http://dx.doi.org/10.1542/peds.103.5.1064. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources